India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
The commercial real estate sector closed out 2025 with renewed stability, as the Real Estate Roundtable’s latest sentiment index shows rising confidence and improving market fundamentals. Executives report better access to capital, stronger performance in residential, retail, and hospitality, and early signs of recovery in the office market. With financing loosening and asset values climbing, the outlook for 2026 is increasingly optimistic, creating fresh opportunities for both seasoned professionals and newcomers preparing to enter the field.
The CFPB is proposing changes to how lenders evaluate “disparate impact” under the Equal Credit Opportunity Act, potentially tightening the scrutiny on credit decisions that unintentionally disadvantage protected groups. These updates could reshape underwriting models, lending criteria, and compliance requirements — ultimately influencing mortgage approvals, buyer qualifications, and day‑to‑day real estate activity.
Florida’s insurance crisis has become the defining issue heading into 2026, with Republicans touting recent market improvements while Democrats argue families are still being crushed by soaring premiums. From billion‑dollar auto insurance refunds to condo markets destabilized by post‑Surfside rate spikes, the state’s political divide is shaping the future of real estate, insurance, and affordability for millions.
October 2025 brought a wave of major regulatory updates across insurance, finance, and compliance. From stricter oversight on retail insurers and new FCA rules on ESG and travel insurance, to EIOPA’s EU‑wide consultations and refreshed corporate governance standards, regulators signaled higher expectations and faster change ahead. For professionals—and those pursuing licenses—these shifts directly impact risk management, product design, and consumer outcomes, making regulatory awareness a critical competitive advantage.
After nearly two years of sluggish activity, commercial real estate lending is finally accelerating—fast. New data from CBRE shows loan closings jumped 112% year‑over‑year in Q3 2025, reaching their highest level since 2018. With interest rates stabilizing and credit spreads tightening, investors are returning, banks are re‑entering the market, and multifamily financing is dominating once again. The long‑stalled deal flow is thawing, signaling renewed momentum heading into 2026.
Farmers Insurance is lifting its cap on new homeowner policies in California after two years of limiting growth, signaling a shift in the state’s strained insurance market. The expansion comes with a proposed 6.99 percent rate increase that still needs regulatory approval. Supporters call it a turning point driven by new wildfire‑risk rules, while consumer advocates warn the reforms contain loopholes and could lead to higher costs for homeowners.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
